newsfilter
← Latest News
Business Wire·

Savara Reports First Quarter Financial Results and Provides Business Update

Achieved Regulatory Milestones for the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP): Biologics License Application (BLA) Filed by the U.S. Food & Drug